白芍总苷联合化疗药物治疗非小细胞肺癌的临床研究

目的 探讨白芍总苷（TGP）联合化疗治疗非小细胞肺癌（NSCLC）的疗效。方法 采用TGP联合化疗治疗NSCLC36例（治疗组），选择同期条件相同．采用单纯化疗治疗NSCLC34例作对照（对照组）；比较两组患者近期疗效、卡氏（Kps）评分、生存质量及细胞免疫变化。结果 KPS改善率分别为31％和9％，恶化率为31％和53％，治疗组KPS评分优于对照组（P〈0．05），生存质量治疗组优于对照组（P〈0．05）。治疗组与对照组比较，细胞免疫CD3、CD4、CD4／CD8比值明显升高，CD8明显下降．差异有统计学意义（P〈0．05）。结论 TGP联合化疗治疗NSCLCKI，S评分优于单纯化疗，并能提高患者生存质量、改善患者细胞免疫功能和升高外周血象。

The clinic research of the combined TGP and chemotherapy remedy for NSCLC

Objective To probe into the curative effects of the combined TGP and chemotherapy remedy for NSCLC.Methods 70 cases were divided into two groups,the treatment group(36 cases),with the combined TGP and chemotherapy remedy for NSCLC and the contrast gronp(34 cases),only with the chemotherapy treatment for NSCLC.Both are based on the same conditions.Then the recent curative effects on the two groups of patients,KSP grades,life quality and cellular immunity were compared.Results The improving rates of KSP were separately 31% and 9%;The worsening rates of KSP were separately 31% and 53%.The KSP grades of the treatment group were better than those of the contrast group(P<0.05).The life quality of the treatment group was better than that of the contrast group(P<0.05).As for the cellular immunity,the ratios of CD_3,CD_4,CD_4/CD_8 rised obviously,while the ratio of CD_8 falls remarkably,and the differences were significant(P<0.05).Conclusion The KSP grads of the combined TGP and chemotherapy remedy for NSCLC are better than those of the chemotherapy treatment.Besides,the combined TGP and chemotherapy remedy proves that it can improve the life quality and the cellular auto-immunity of the patients,and have effect on the growth of the leukocytes in the peripheral region.